首页> 外文期刊>Molecular biology of the cell >Proteasome Regulates the Delivery of LDL Receptor-related Protein into the Degradation Pathway
【24h】

Proteasome Regulates the Delivery of LDL Receptor-related Protein into the Degradation Pathway

机译:蛋白酶体调节LDL受体相关蛋白向降解途径的传递。

获取原文
           

摘要

The low-density lipoprotein receptor (LDLR)-related protein (LRP) is a multiligand endocytic receptor that has broad cellular and physiological functions. Previous studies have shown that both tyrosine-based and di-leucine motifs within the LRP cytoplasmic tail are responsible for mediating its rapid endocytosis. Little is known, however, about the mechanism by which LRP is targeted for degradation. By examining both endogenous full-length and a minireceptor form of LRP, we found that proteasomal inhibitors, MG132 and lactacystin, prolong the cellular half-life of LRP. The presence of proteasomal inhibitors also significantly increased the level of LRP at the cell surface, suggesting that the delivery of LRP to the degradation pathway was blocked at a compartment from which recycling of the receptor to the cell surface still occurred. Immunoelectron microscopy analyses demonstrated a proteasomal inhibitor-dependent reduction in LRP minireceptor within both limiting membrane and internal vesicles of the multivesicular bodies, which are compartments that lead to receptor degradation. In contrast to the growth hormone receptor, we found that the initial endocytosis of LRP minireceptor does not require a functional ubiquitin–proteasome system. Finally, using truncated cytoplasmic mutants of LRP minireceptors, we found that a region of 19 amino acids within the LRP tail is required for proteasomal regulation. Taken together our results provide strong evidence that the cellular turnover of a cargo receptor, i.e., LRP, is regulated by the proteasomal system, suggesting a broader function of the proteasome in regulating the trafficking of receptors into the degradation pathway.
机译:低密度脂蛋白受体(LDLR)相关蛋白(LRP)是一种多配体内吞受体,具有广泛的细胞和生理功能。先前的研究表明,LRP胞质尾巴中的基于酪氨酸和双亮氨酸的基序均是介导其快速内吞的原因。但是,关于LRP降解的机制知之甚少。通过检查LRP的内源性全长和微受体形式,我们发现蛋白酶体抑制剂MG132和lactyacystin可延长LRP的细胞半衰期。蛋白酶体抑制剂的存在还显着增加了细胞表面LRP的水平,这表明LRP到降解途径的传递在仍然发生受体循环到细胞表面的隔室被阻断。免疫电子显微镜分析表明,在多囊泡体的限制膜和内部囊泡(既是导致受体降解的区室)中,蛋白酶体抑制剂依赖性的LRP微受体的减少。与生长激素受体相反,我们发现LRP minireceptor的初始内吞作用不需要功能泛素-蛋白酶体系统。最后,使用LRP minireceptor的截短的胞质突变,我们发现LRP尾部内19个氨基酸的区域是蛋白酶体调节所必需的。综上所述,我们的结果提供了有力的证据,表明货物受体即LRP的细胞更新受到蛋白酶体系统的调节,表明蛋白酶体在调节受体向降解途径的运输中具有更广泛的功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号